Clinical trial · Interventional
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
MRI-guided Bone Marrow Biopsies of Advanced CaP Patients
NCT00165386CI-TRIAL-00002870completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to target lesions of the prostate in the bone and to biopsy these lesions using MRI to identify the areas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bone Marrow Biopsy | Procedure | — | UNRESOLVED |
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
Secondary outcomes (1)
- measure
- To evaluate the sensitivity of radiographic bone marrow changes detected by MRI for prostate cancer, as determined by the pathologic findings from bone marrow biopsy.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of prostate cancer * Bone scan consistent with or suspicious of metastatic prostate cancer within last three months * Platelet count \> 50,000/ul * PT and aPTT \< 1.5 x control * At least one week removed from taking aspirin or coumadin * Currently participating in protocol "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer" Exclusion Criteria: * Devices incompatible to MR studies (e.g. pacemakers, ear implants, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.